
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
In this video, Melissa R. Kaufman, MD, PhD, FACS, discusses the takeaways from the study, “A double-blind, randomized, controlled trial comparing safety and efficacy of autologous muscle derived cells for urinary sphincter repair (AMDC-USR) with placebo (PBO) in women with stress urinary incontinence (SUI),” presented during the 2021 American Urological Association annual meeting. Kaufman is a professor of urology and chief of the division of reconstructive urology and pelvic health at Vanderbilt University, Nashville, Tennessee.

